News
Melanoma Treatment Advances – 2018 in Review
By Marc Hurlbert, PhD, MRA Chief Executive Officer | 18 January 2019 In Science, Treatment
2018 brought new and expanded drug approvals that give patients, doctors, and their families more treatment options with fewer side effects. Learn more about important melanoma treatment advances in 2018.
From Health Scare to Transformative Change
By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 16 January 2019 In Melanoma Stories
Debra Black founded the Melanoma Research Alliance in 2007 after her own diagnosis with Stage II disease earlier that year. Since then, MRA has become the largest, non-profit funder of melanoma research worldwide.
Make Your Sun Safety Habit Stick: La Roche Posay’s My Skin Track UV
By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 3 January 2019 In Allies & Partnerships, Prevention
Last month’s arrival of La Roche Posay’s My Skin Track UV may be just what the doctor ordered to help people understand the danger of overexposure to ultraviolet radiation.
MRA Advisor & Grantee Dr. Allison Awarded Nobel Prize for Transforming Cancer Care
By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 28 November 2018 In News, Science, Treatment
MRA Scientific Advisory Panel Member & Grantee Dr. Allison Awarded Nobel Prize for his pioneering research to harness the power of the immune system to attack cancer. His work in immunotherapy, which began in the 1990’s, was audacious at the time. It helped to mainstream an entirely new class of tools in the arsenal against cancer; joining the likes of chemotherapy, radiation, and surgery.
Dr. Marc Hurlbert Joins MRA as Chief Science Officer
By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 20 November 2018 In Science
Dr. Marc Hurlbert has built his career advancing medical research in support of patients. Now, as of this month, he will translate his skills, relationships, and enthusiasm to achieving our mission of ending death and suffering due to melanoma as MRA’s Chief Science Officer.
When Astrophysics & Melanoma Collide
By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 16 November 2018 In Science
Using lessons, processes, and tools from the field of astrophysics, Dr. Taube is studying melanoma in all new ways.
Improving the Lives of Melanoma Survivors
By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 15 October 2018 In Prevention, Science
Melanoma survivors are at a 9-fold increased risk of developing another melanoma. Unfortunately, 20% of survivors reported a sunburn in the past year and 10% intentionally went outside for a tan – both strong predictors of inappropriate sun exposure.
Older Patients Do Better on Immunotherapy
By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 8 October 2018 In Science, Treatment
In Dr. Weeraratna's study, older patients did better on immunotherapy than younger patients. This surprising result is the opposite of what was expected.
For Kimberly, Clinical Trials Were a Leap of Faith
1 October 2018 In Melanoma Stories
Kimberly was just 19-years-old when she noticed the black “freckle” on her foot. But it wasn’t until she was 22-years-old and pregnant with her first child that her “freckle” became a cause for concern.
Ipilimumab Cured Dan Engel He’s Committed to Paying it Forward
By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 24 September 2018 In Melanoma Stories
Dan needed a miracle. At this point, he’d had six surgeries on his neck, endured radiation therapy, and been enrolled in five clinical trials. Dan’s miracle came in 2006 in the form of an experimental drug, ipilimumab or anti-CTLA4 antibody, that would later be named Yervoy. This drug would later become the first new FDA-approved melanoma treatment in 13 years.